Novel Mutations in TACSTD2 Gene in Families with Gelatinous Drop-like Corneal Dystrophy (GDLD)

Elham Alehabib¹, Javad Jamshidi², Hamid Ghaedi³, Babak Emamalizadeh³, Monavvar Andarva¹, Narsis Daftarian⁴, Mozhgan Rezaei Kanavi⁴, Peyman Mohammadi Torbati⁵, Goldis Espandar⁴, Somayeh Alinaghi¹, Amir Hossein Johari¹, Mansoor Saghally¹, Fatemeh Mohajerani¹, Hossein Darvish¹

1. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
3. Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
4. Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5. Department of Pathology, Labbafi-Nezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

In the current study, we conducted a mutation screening of tumor-associated calcium signal transducer 2 (TACSTD2) gene in six consanguineous Iranian families with gelatinous drop-like corneal dystrophy (GDLD), in order to find the causative mutations. Detailed eye examination was performed by ophthalmologist to confirm GDLD in patients. To detect the possible mutations, direct Sanger sequencing was performed for the only exon of TACSTD2 gene, and its boundary regions in all patients. In the patients with GDLD, the corneal surface showed lesions with different shapes from mild to severe forms depending on the progress of the disease. The patients showed grayish corneal deposits as a typical mulberry form, corneal dystrophy along with corneal lipid deposition, and vascularization. Targeted Sanger sequencing in TACSTD2 gene revealed the causative mutations in this gene in all studied families. Our study expanded the mutational spectrum of TACSTD2 which along with the related symptoms could help with the diagnosis, and management of the disease.

Key words: Gelatinous drop-like, corneal dystrophy, GDLD; TACSTD, Iranian

Gelatinous drop-like corneal dystrophy (GDLD) (OMIM#204870) is a type of eye disorder in which the patients lose their vision because of amyloid deposition on the cornea. Based on the international committee for classification of corneal dystrophies (IC3D) classification, GDLD is a member of sub epithelial dystrophies (1). This rare disorder is inherited as an autosomal recessive
trait. GDLD appears in the first or second decade of life, and usually leads to blindness as its natural course (2). It is well-known that the causative gene for GDLD is tumor-associated calcium signal transducer 2 (TACSTD2), which was identified by Tdujikawa et al. in 1998 (3). TACSTD2 has one exon with 972 nucleotides, and encodes for a protein with 323 amino acids (3). TACSTD2 acts as a calcium signal transducer, and has receptor function activity (4). In patients with GDLD, superficial cells in cornea do not express claudin 1, tight junction protein 1, and occludin, in addition to stability change in cell-to-cell junctions. These findings suggest that any pathogenic alterations in TACSTD2 gene, due to loss of function, changes the permeability in epithelial cells that lead to clinical symptoms in cornea (5). Decreased epithelial barrier function, eases lactoferrin - an iron- binding glycoprotein present in exocrine fluids- deposition on the cornea, which eventually leads to amyloid deposition (6-7). It has been reported that the phenotypic variability in GDLD could be due to age-related progression over time (8). However, a recent study in a consanguineous Colombian family with 5 affected patients suggested that environmental or other genetic factors may also affect the manifestation of clinical symptoms (8). The other aspect of TACSTD2 gene, is its over expression relation with tumor cells. The role of TACSTD2 gene in progression and aggressiveness of colorectal cancer has been confirmed in different studies (9-12), but coincidence of colorectal cancer in patients with GDLD has been less considered. Prevalence of GDLD has not been determined in Iran, and previous studies have revealed some pathogenic mutations in Iranian population. In the current study, we investigated six consanguineous Iranian families with GDLD to detect the causative mutations and explain the symptoms related to each mutation and family.

Materials and methods

Subjects

This is a descriptive study conducted in six consanguineous Iranian families with GDLD referred from Mazandaran, Khouzestan, Tehran and Isfahan to Labbafinejad Hospital (Tehran, Iran). Clinical investigations were performed according to the Declaration of Helsinki, and all the families signed the informed consent for participating in this study. The Ethical Committee of Shahid Beheshti University of Medical Sciences approved this study.

Six consanguineous Iranian families with at least two patients with GDLD were involved in our study. The pedigrees of these families are shown in Figure 1. The diagnosis of GDLD was performed by ophthalmologist, based on clinical manifestations, ocular examination, and histopathology evaluation of cornea tissue.

Ocular examinations

Uncorrected visual acuity was performed using the standard 20 feet Snellen acuity chart. Best corrected visual acuity tests, and intraocular pressure were not possible to undertake because of severe photophobia and corneal opacity. Complete slit-lamp bio microscopy examinations including the conjunctiva, cornea, anterior chamber clarity, angle and iris were done as much as possible by the corneal opacity evaluation.

Histopathology assessment

Patients’ corneas, fixed in 10% formalin were bisected, processed, and embedded in paraffin blocks. Thin tissue sections were stained with hematoxylin and eosin, periodic acid-Schiff (PAS), Masson’s Trichrome, and Congo-red staining methods. All stained slides were examined under light microscopy (BX41, Olympus, Japan), and photographed with a digital camera (DP12 Microscope Camera, Olympus, Japan).

Molecular analysis

DNA was obtained from white blood cells in peripheral blood using a standard salting-out method (13). Three pairs of primers were designed for the only exon of TACSTD2 using primer 3
program. The sequence of the three primer pairs are as follows: first pair (Forward: 5′-TGCAGACCAT- CCCAGACG-3′, Reverse: 5′-TAGAGGCCATC- GTGTCCAC-3′) second pair (Forward: 5′- CAAGTGTCTGCTGCTCAAGG-3′, Reverse: 5′- CTCGATCTGGATGGTGGGC-3′) and third pair (Forward: 5′-GCTGCACCCCAAGTTCGT-3′, Reverse: 5′- GACTCACTTGGGTCTGGGAC-3′).

Polymerase chain reaction (PCR) was performed for all patients’ samples, and products were sequenced by directed Sanger sequencing with Applied Biosystems BigDye terminator v3.1 sequencing chemistry on an ABI3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA). Then, the sequence data were compared to reference sequence of the gene, available at the National Center for Biotechnology Information (NCBI), and analyzed using Sequencer 5.0 software (Gene Codes Corporation, Ann Arbor, MI, USA). Familial segregation of the mutations, in each family was also performed by targeted Sanger sequencing of the gene in other family members. The detected mutations were also confirmed using sequencing with the reverse primer.

**Bioinformatics analysis**

To assess the potential functional impact of the Glu227Lys and Pro266Leu, we utilized four widely used algorithms to perform in silico analysis: SIFT (sorting intolerant from tolerant), PolyPhen-2 (polymorphism phenotyping-2), Align GVGD (align Grantham variation Grantham deviation), and I- Mutant v.2. In general, these four tools all have distinct algorithms with variable, however, high prediction accuracy.
Novel Mutations in TACSTD2 Gene

Results

Phenotype of patients

Six consanguineous Iranian families with GDLD were studied. The clinical characteristics of patients in each family are presented in Table 1. Slit lamp photographs of the corneas (related to II.2 and II.3 in family 4) are presented in Figure 2. Slit lamp photographs in the other affected individuals were not performed because of no significant clinical feature or surgical operation.

Histopathological examinations disclosed full cornea thickness with a prominent band-shaped eosinophilic amorphous material underlying an irregular corneal epithelium. The deposits were slightly PAS-reactive, and stained positively on Congo red which revealed a red apple green birefringence—the sign of the presence of amyloid fibrils—under polarized light (Figure 3). The microscopic features were diagnostic of a GDLD.

TACSTD2 mutation analysis

GDLD-causing mutations were detected in all the patients within TACSTD2 gene (Table 1). Five different mutations were found including: p.Cys66*, p.Glu227Lys, p.Lys84Glnfs*11, p.Gly165Profs*15, and p.Pro266Leu. The nucleotide alteration which caused the amino acid substitution, Pro266Leu, was also assessed in 100 unrelated control individuals by targeted Sanger sequencing, and was not observed in them.

Pathogenicity predictions for novel missense mutations identified in our study (p.Glu227Lys and p.Pro266Leu) are presented in Table 2.

Discussion

In the current study, we investigated six Iranian families with GDLD. We screened TACSTD2 gene to detect the possible mutations related to this condition in our patients. The pathogenic mutations were found in all six studied families in TACSTD2 gene. Two of these mutations (p.Cys66*, p.Glu227Lys) were previously reported (14) and three of them (p.Lys84Glnfs*11, p.Gly165Profs*15 and p.Pro266Leu) were novel based on Exome Aggregation Consortium (ExAC...
Table 1. Clinical Features of GDLD patients.

<table>
<thead>
<tr>
<th>No.</th>
<th>Curr. age</th>
<th>Age of onset</th>
<th>Sex</th>
<th>Mutation</th>
<th>BCVA (Snellen)</th>
<th>Phenotypic expression (Type of Amyloidosis)</th>
<th>Vascularization</th>
<th>Site of Amyloidosis</th>
<th>Unilateral/bilateral affected</th>
<th>Relative Severity</th>
<th>Progression (Recurrence*)</th>
<th>Treatment strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20 y</td>
<td>12 y</td>
<td>F.</td>
<td>c.198C&gt;A</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Total cornea</td>
<td>Bilateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>Lamellar Keratoplasty</td>
</tr>
<tr>
<td>2</td>
<td>18 y</td>
<td>6 y</td>
<td>F.</td>
<td>(p.Cys66*)</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Total cornea</td>
<td>Bilateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>Lamellar Keratoplasty</td>
</tr>
<tr>
<td>2'</td>
<td>28 y</td>
<td>15 y</td>
<td>M.</td>
<td>c.249_250insC (p.Lys84Glnfs*)</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Total cornea</td>
<td>Bilateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>Keratoplasty</td>
</tr>
<tr>
<td>3</td>
<td>25 y</td>
<td>13 y</td>
<td>F.</td>
<td>(11)</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Total cornea</td>
<td>Bilateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>Keratoplasty</td>
</tr>
<tr>
<td>4</td>
<td>17 y</td>
<td>16 y</td>
<td>F.</td>
<td>c.492_493insC</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Central</td>
<td>Mon lateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>SK OU, LK OU</td>
</tr>
<tr>
<td>5</td>
<td>12 y</td>
<td>6 y</td>
<td>F.</td>
<td>Gly165Phdel+15</td>
<td>C.F.</td>
<td>mulberry</td>
<td>No</td>
<td>Central</td>
<td>Bilateral</td>
<td>severe</td>
<td>Progressive &amp; recurrency</td>
<td>SK OU, LK OU</td>
</tr>
<tr>
<td>6</td>
<td>47 y</td>
<td>at birth</td>
<td>F.</td>
<td></td>
<td></td>
<td>Hand motion (both eyes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>45 y</td>
<td>2 y</td>
<td>F.</td>
<td>c.679G&gt;A</td>
<td></td>
<td>Hand motion (both eyes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>35 y</td>
<td>2 y</td>
<td>F.</td>
<td>(p. Gln227Lys)</td>
<td></td>
<td>Counting finger at 20 cm (RE) Hand motion (LE)</td>
<td>Not evaluable because of previous surgeries</td>
<td>Central corneal</td>
<td>Recurrence in both eyes after surgeries</td>
<td>Progressive and keratoplasty (LE)</td>
<td>Lamellar keratoplasty (LE)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>31 y</td>
<td>12 y</td>
<td>F.</td>
<td></td>
<td></td>
<td>Typical mulberry</td>
<td>No</td>
<td>Central</td>
<td>Bilateral</td>
<td>Severe</td>
<td>Progressive &amp; recurrency</td>
<td>Keratoplasty</td>
</tr>
<tr>
<td>10</td>
<td>55 y</td>
<td>12 y</td>
<td>M.</td>
<td></td>
<td>RE: LP, LE: CF</td>
<td>Severe, mulberry</td>
<td>Central corneal</td>
<td>Severe</td>
<td></td>
<td></td>
<td>Progressive &amp; recurrency</td>
<td>Lamellar keratoplasty (both eyes)</td>
</tr>
<tr>
<td>11</td>
<td>45 y</td>
<td>3 y</td>
<td>M.</td>
<td>c.679G&gt;A</td>
<td>RE: LP, LE: CF</td>
<td>Severe, mulberry</td>
<td>Central corneal</td>
<td>Severe</td>
<td></td>
<td></td>
<td>Progressive &amp; recurrency</td>
<td>Lamellar keratoplasty (both eyes)</td>
</tr>
<tr>
<td>12</td>
<td>38 y</td>
<td>6 month</td>
<td>F.</td>
<td></td>
<td>RE: LP, LE: CF</td>
<td>Severe, mulberry</td>
<td>Central corneal</td>
<td>Severe</td>
<td></td>
<td></td>
<td>Progressive &amp; recurrency</td>
<td>Lamellar keratoplasty (both eyes)</td>
</tr>
<tr>
<td>13</td>
<td>50 y</td>
<td>7 y</td>
<td>F.</td>
<td>c.797C&gt;T</td>
<td>C.F.</td>
<td>Typical mulberry</td>
<td>No</td>
<td>Central</td>
<td>Bilateral</td>
<td>Severe</td>
<td>Progressive &amp; recurrency</td>
<td>Penetrating keratoplasty</td>
</tr>
<tr>
<td>14</td>
<td>F.45</td>
<td>7 y</td>
<td>F.</td>
<td>(p. Pro266Leu)</td>
<td>C.F.</td>
<td>Typical mulberry</td>
<td>No</td>
<td>Central</td>
<td>Bilateral</td>
<td>Severe</td>
<td>Progressive &amp; recurrency</td>
<td>Penetrating keratoplasty</td>
</tr>
</tbody>
</table>

BCVA: Best Corrected Visual Acuity; CF: Counting Fingers; F: Female; LE: Left Eye; LP: Light Perception; M: Male; RE: Right Eye; Y: year,
Novel Mutations in TACSTD2 Gene

TACSTD2 codes for a protein with a single-transmembrane domain (AA 275–297), an epidermal growth factor-like repeat, a thyroglobulin domain, and a phosphatidylinositol 4, 5-bisphosphate-binding domain. This monomeric cell surface glycoprotein is present in organs such as cornea, placenta, trophoblasts, pancreas, kidney, pancreas, prostate, lung, and colon. Expression of this gene has been also reported in some carcinomas (14). TACSTD2 is a CpG rich gene, and has 22 SNPs, which may affect the function, and expression of this gene. Due to the presence of CpG islands in the majority of TACSTD2 regions, it seems that expression of this gene is impressed by epigenetic regulation (7).

p.Cys66* mutation, which was found in family 1, causes a truncated protein after about one fifth of the mRNA translation. In the previous report, patient with this mutation had not shown the initial symptoms in early life, and the clinical signs started at the second decade of life (15). In our family with the same mutation, the age of onset was earlier, and it was also different between affected individuals in the family.

p.Lys84Glnfs*11 and p.Gly165Profs*15, two of the novel mutations, are the consequence of nucleotide insertion, which leads to a frame shift, early stop codon, and truncated protein. p.Gly165Profs*15, p.Glu227Lys, and p.Pro266Leu occurred between the thyroglobulin-like (TY) and transmembrane (TM) domains of the protein. According to the schematic representation of mutation spectrum in TACSTD2 gene (Figure 4), which is prepared in accordance with reported mutations up to now, about 50 percent of all deleterious mutations in TACSTD2 gene occur between the TY and TM domains. The exact function of this region is not known (15).

The mutation in family 3 was an eight-nucleotide insertion (c.492_493insCCACCGCC (p.Gly165Profs*15)) that leads to a frame shift. The two patients in this family manifested the disease

<table>
<thead>
<tr>
<th>Mutation</th>
<th>SIFT score (prediction)</th>
<th>Polyphen score (prediction)</th>
<th>Align GVGD</th>
<th>I-mutant stability score (prediction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glu227Lys</td>
<td>0 (damaging)</td>
<td>1.00 (probably damaging)</td>
<td>damaging (Class 55)*</td>
<td>6 (decreased)</td>
</tr>
<tr>
<td>Pro266Leu</td>
<td>0.01 (damaging)</td>
<td>1.00 (probably damaging)</td>
<td>damaging (Class 65)*</td>
<td>5 (decreased)</td>
</tr>
</tbody>
</table>

Fig. 4. The schematic representation of mutations spectrum in TACSTD2.

Table 2. Pathogenicity predication for novel missense mutations identified

<table>
<thead>
<tr>
<th>Mutation</th>
<th>SIFT score (prediction)</th>
<th>Polyphen score (prediction)</th>
<th>Align GVGD</th>
<th>I-mutant stability score (prediction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glu227Lys</td>
<td>0 (damaging)</td>
<td>1.00 (probably damaging)</td>
<td>damaging (Class 55)*</td>
<td>6 (decreased)</td>
</tr>
<tr>
<td>Pro266Leu</td>
<td>0.01 (damaging)</td>
<td>1.00 (probably damaging)</td>
<td>damaging (Class 65)*</td>
<td>5 (decreased)</td>
</tr>
</tbody>
</table>
differently; in addition to different age of onset, in one of them both eyes were involved, and in another patient only one eye was involved, although she may develop the disease to the other eye later in her life.

p.Glu227Lys which was detected in two families in our study (F4 and F5), has been reported before, and was introduced as a founder mutations in Iranian population (15). Glutamic acid in this site is conserved in TACSTD2 gene, and located between TY-TM domains. We saw variable phenotypic expression, and different age of onset in patients with this mutation in the same family, and also between the patients of the two families (F4 and F5). This mutation is one of the nucleotide alterations that are related with severe form of GDLD, because the patients with this mutation experience the amyloid deposition in early life with severe form of GDLD. A study also has reported paracentral amyloid deposition on the cornea in some patients with this mutation, which may indicate the involvement of other factors in determining the clinical manifestation of the disease (15). An interesting finding is that one of our patients with this mutation (F5P2) had history of intestinal problems with the diagnosis of adenocarcinoma. He had colonoscopy for removing the polyps. Association of adenocarcinoma with GDLD was also reported previously for a different mutation (p.Tyr184Cys) (8).

p. Pro266Leu, as a novel mutation, was discovered in family 6, and the pathogenicity of this amino acid substitution was confirmed with bioinformatics tools. Moreover, this mutation was not seen in 100 normal individuals examined for this alteration, which support its pathogenicity.

Deleterious homozygous mutations, such as the mutations in our families, usually cause loss of function in TACSTD2 gene. To date about 33 mutations, in TACSTD2 gene have been reported from different geographical regions including Japan, Iran, India, Tunisia, China, Estonia, Turkey, Vietnam, Colombia, Latin America, Thailand, and Europe (6, 8, 14-22). The evidence from Japan suggests that the prevalence of GDLD is higher in this country, about 1 in 31,000 (23).

Some patients with amyloid deposition on the cornea have been reported previously that did not show pathogenic nucleoid alteration in TACSTD2 gene. In these cases, two other candidate genes transforming growth factor beta induced (TGFBI) and gelsolin (GSN) were assessed. Evidence showed that pathogenic nucleotide alteration in these two genes also lead to amyloid deposition, although their inheritance, and clinical signs are different from GDLD (14).

In conclusion, in the current study, we introduced three novel mutations in TACSTD2 gene which cause GDLD. Our study expanded the mutational spectrum of TACSTD2 gene, which along with the related symptoms could help with the diagnosis and management of the disease. Functional studies are needed to clarify the molecular mechanisms which lead to GDLD due to mutations in TACSTD2 gene.

Acknowledgments

We would like to thank our patients and their families for their participation. This study was funded by Shahid Beheshti University of Medical Sciences.

Conflict of interest

The authors disclose that there is no conflict of interest.

References

Novel Mutations in TACSTD2 Gene